Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

The purpose of this study was to evaluate the pharmacokinetics of intranasal ... and 3.38 μg/L for treatments B and C, respectively. Mean (% coefficient of variation) bioavailability of ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S.

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...

Arrowhead Pharmaceuticals, Inc. today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being ...

Objective: Spalt-Liqua® is a newsoft gelatin capsule containing 200mg of totally dissolved ibuprofen as the active ingredient. The primary objective of the study was to assess bioequivalence ...

Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25 ...

Shares of biotechnology company Rigel Pharmaceuticals, Inc. RIGL have surged 41.4% in the past year against the industry’s ...

Geographic expansion and regulatory expertise: With an increasingly complex global regulatory environment, biopharma ...